Lipella Pharmaceuticals Inc.
LIPO
$2.52
$0.031.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 19.31% | 0.77% | 35.00% | 77.51% | 144.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.31% | 0.77% | 35.00% | 77.51% | 144.22% |
| Cost of Revenue | 18.90% | -1.88% | -3.08% | 74.88% | 68.35% |
| Gross Profit | -18.83% | 2.38% | 8.80% | -74.43% | -59.74% |
| SG&A Expenses | -7.09% | 2.49% | 60.71% | 238.24% | 853.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.11% | -0.27% | 15.97% | 67.05% | 87.31% |
| Operating Income | -7.05% | 0.38% | -14.06% | -66.10% | -83.26% |
| Income Before Tax | -8.60% | 0.71% | -12.44% | -62.02% | -77.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.60% | 0.71% | -12.44% | -62.02% | -77.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.60% | 0.71% | -12.44% | -62.02% | -77.81% |
| EBIT | -7.05% | 0.38% | -14.06% | -66.10% | -83.26% |
| EBITDA | -143.50% | -221.14% | -- | -- | -- |
| EPS Basic | 23.99% | 28.26% | 12.92% | -18.37% | -20.92% |
| Normalized Basic EPS | 23.99% | 28.26% | 12.92% | -18.37% | -20.92% |
| EPS Diluted | 24.64% | 28.76% | 13.59% | -18.03% | -21.97% |
| Normalized Diluted EPS | 23.99% | 28.26% | 12.92% | -18.37% | -20.92% |
| Average Basic Shares Outstanding | 39.64% | 41.49% | 37.15% | 41.09% | 47.86% |
| Average Diluted Shares Outstanding | 39.64% | 41.49% | 37.15% | 41.09% | 47.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |